Welcome to our dedicated page for Puma Biotechnology news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology stock.
Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Puma Biotechnology (NASDAQ: PBYI) presented promising findings from a Phase II study of alisertib for endocrine and CDK4/6 inhibitor-resistant, HER2-negative, hormone receptor-positive metastatic breast cancer at the 2024 ASCO Annual Meeting.
The study compared alisertib alone versus alisertib plus fulvestrant, showing overall response rates of 19.6% and 20.0%, respectively. Median progression-free survival was 5.6 months for alisertib and 5.4 months for the combination therapy, both indicating tolerable safety profiles.
Key biomarker findings include decreased progression-free survival in patients with PIK3CA mutations and longer progression-free survival associated with lower circulating tumor cell counts and lower methylated tumor fraction percentages. Ongoing analyses aim to identify patients who may benefit most from alisertib.
Puma Biotechnology (NASDAQ: PBYI) will join the Russell 3000 Index starting July 1, following the annual reconstitution of Russell Investments' equity indexes. This inclusion is based on market-capitalization rankings as of the end of April.
Membership in the Russell 3000 will also mean automatic inclusion in either the Russell 1000 Index or Russell 2000 Index, and relevant growth and value style indexes. It offers increased liquidity and broader exposure to institutional investors, benefiting stockholders.
The Russell indexes, utilized by investment managers and institutional investors, benchmark over $10 trillion in assets. This is a significant development for Puma Biotechnology, aligning them with major U.S. and global equity performance metrics.
Puma Biotechnology announced the release of abstracts on its drug alisertib, which will be presented at the 2024 ASCO Annual Meeting. The event, scheduled from May 31 to June 4 in Chicago and online, will feature two key studies involving alisertib. The first, Abstract 1037, is a phase II study on alisertib in treating endocrine-resistant metastatic breast cancer, with findings presented by Dr. Karthik Giridhar from Mayo Clinic. The second, Abstract 8572, explores a phase I/Ib study of alisertib combined with osimertinib for osimertinib-resistant EGFR-mutated lung cancer, presented by Dr. Turja Chakrabarti from the University of California, San Francisco. Full abstracts are available online.
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported its first quarter financial results for 2024, with $40.3 million in product revenue, a net loss of $4.8 million, and $107.2 million in cash reserves. Key milestones include clinical trials for lung and breast cancer treatments. Total revenue was $43.8 million, with operating costs of $46.1 million. Second quarter and full-year 2024 financial outlook projects net product revenue of $43-45 million and $183-190 million, respectively.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.